David Fajgenbaum: It’s a common misconception that approval marks the peak of a drug’s journey

David Fajgenbaum shared on X:

“When a drug receives FDA approval, its research and development (R&D) often shifts away from further exploration into new indications.

It’s a common misconception that approval marks the peak of a drug’s journey.

In reality, it’s the opposite.

When the drug eventually turns generic, it becomes more affordable and accessible than ever. Yet paradoxically, this is when R&D typically comes to a standstill.

As someone whose life was saved by an old, generic drug, I am deeply invested in this topic. We should be maximizing these opportunities, not diminishing them.

At Every Cure, we are on a mission to shift the narrative and focus on how we can leverage these accessible drugs to their fullest potential.

What are your thoughts on how we can reinvigorate R&D for generic drugs to enhance their impact and accessibility?”

Source: David Fajgenbaum/X